FIG 3.

The IL-15–IFN-α combination treatment induces immune-mediated liver damage in HBVTg mice but not in WT mice. (A) Representative images of necroinflammatory lesions in HBVTg (top) and C57BL/6 (bottom) mice on day 20 after vector administration. (B) TUNEL-positive nuclei (right) and 4′,6-diamidino-2-phenylindole (DAPI) staining (left) of the same mice. (C) Serum ALT levels in HBVTg mice at days 10 and 20 after vector administration. Results are expressed as means ± SEM for 5 to 6 animals/group (***, P < 0.001).